AI in Drug Discovery and Development Market is set for steady growth to US$ 34.05 billion by 2033, at a Strong CAGR of 18.5%. North America leads the market with 67.2% market share | Major M&A and Tech partnership

The Global AI in drug discovery and development market reached US$ 6.24 billion in 2024 and is expected to reach US$ 34.05 billion by 2033, growing at a CAGR of 18.5% during the forecast period 2025-2033.

AI in drug discovery and development market growth is driven by faster target identification, reduced R&D costs, improved clinical success rates, big data availability, and rising demand for personalized, precision medicines.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/ai-in-drug-discovery-and-development-market?prtk

United States: Key Industry Developments

✅ January 2026: U.S. AI drug discovery market reached $2.86 billion valuation with 10.26% CAGR projected through 2035, driven by FDA's accelerated approval pathway for AI-identified candidates.

✅ December 2025: Recursion Pharmaceuticals licensed its AI platform to Roche/Genentech for $150M+ upfront, accelerating antibody discovery across 15+ targets using massive bioimage datasets.

✅ October 2025: Insilico Medicine advanced ISM001-055 into Phase II trials using generative AI de novo design, completing target-to-FIH in 30 months versus industry 5-year average.
​
Asia Pacific / Japan: Key Industry Developments

✅ January 2026: Japan established national AI Drug Discovery Consortium with 40+ pharma firms, targeting 20% R&D cost reduction through shared foundation models and datasets.

✅ November 2025: Exscientia Japan launched AI-designed oncology candidate into Phase I, achieving 70% binding affinity improvement over traditional high-throughput screening.

✅ September 2025: WuXi AppTec expanded AI capabilities with $200M supercomputing cluster, supporting 100+ virtual screening campaigns monthly across APAC partnerships.

Ai in drug discovery and development Market Recent M&A activities:-
→ In January 2026, Eli Lilly entered a collaboration with Repertoire Immune Medicines valued at up to $1.93 billion to co-develop autoimmune therapies using Repertoire's AI-linked DECODE platform, including an $85 million upfront payment and tiered royalties.

→ In January 2026, Eli Lilly signed a deal with Seamless Therapeutics worth up to $1.12 billion to access Seamless's gene-editing technology for therapeutic development, including upfront and R&D funding plus milestone payments.

→ In October 2025, Nanyang Biologics completed a reverse merger via SPAC RF Acquisition Corp II to bring its AI-enabled small-molecule platform public, valuing the company at up to $1.5 billion (expected close Q1-Q2 2026).

→ In September 2025, Novartis and Monte Rosa Therapeutics announced a licensing deal valued at up to $5.7 billion for AI-powered molecular glue degraders targeting immune-mediated diseases, with a $120 million upfront payment and milestone/royalty potential.

Ai in drug discovery and development Market key Players:-
Alphabet (Google DeepMind) | Atomwise Inc.| BenevolentAI | BioMap| BioSymetrics | DEEP Genomics | Euretos | Exscientia | IBM, and Iktos.

Top 5 Key Players Analysis:-
Alphabet (Google DeepMind): 22% Market Share
Google DeepMind leads with AlphaFold3 protein structure prediction platform used by 70% top pharma firms, compressing discovery timelines 40%.​
Isomorphic Labs leverages same tech for $3B+ Sanofi partnership across 15 novel targets.

Exscientia: 15% Share
UK-based Exscientia pioneered first AI-designed drug into Phase II trials, partnering Bristol Myers Squibb for $700M oncology pipeline.​
Precision chemistry platform designs clinical-ready molecules in 8 months vs industry 4-year average.

BenevolentAI: 12% European Share
BenevolentAI's knowledge graph identified baricitinib for COVID-19 treatment in 2 weeks, now advancing ALS/IBD candidates.​
Platform analyzes 100TB biomedical data daily, generating 50+ novel targets annually.

Atomwise: 10% Small Molecule Share
Atomwise AtomNet screens 3 trillion compounds virtually, partnering Lilly/AstraZeneca for $100M+ programs across antivirals and oncology.​
Convolutional neural networks predict binding affinity with 90% accuracy vs 65% traditional docking.

DEEP Genomics: 8% Genomics Share
Canadian AI firm designs antisense oligonucleotides using DeepTuning ML, advancing neuromuscular disease candidates into clinic.​
RNA splicing prediction platform analyzes 1M variants/second, identifying 3x more therapeutic targets.

Ai in drug discovery and development Market Top Technological Partnerships (2026 & 2025):-

Insilico Medicine + Servier (Jan 2026): $888M oncology deal leverages Pharma.AI platform for novel target discovery, with $32M upfront payment accelerating 6+ clinical candidates.

Recursion + Roche/Genentech (Dec 2025): $150M+ licensing expands AI bioimage platform across 15 targets, compressing antibody discovery timelines 40% using massive phenotypic datasets.​

Eli Lilly + Creyon Bio (Nov 2025): Multi-target RNA oligonucleotide partnership utilizes AI-powered oligo engineering engine for broad disease applications.

AstraZeneca + BenevolentAI (Oct 2025): Expanded machine learning collaboration drives target identification and drug repurposing across immunology pipeline.

Sanofi + Insilico Medicine (Sep 2025): $110M Series E fuels Pharma.AI expansion for 6 novel targets, predicting clinical outcomes with 85% accuracy.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=ai-in-drug-discovery-and-development-market?prtk

Ai in drug discovery and development Market Market Drivers :-
▪ R&D Cost Crisis Triggers AI Revolution
$2.6B Average Drug Cost: AI slashes discovery expenses 60% from $2.6B to $1B by virtual screening 10B+ compounds/second vs 1M traditional methods.
​12-Year Timeline Compression: Target-to-FIH drops from 5 years to 18 months, with Insilico completing Phase II candidate in 30 months vs industry 60-month average.
​
▪ AlphaFold3 Unlocks Protein Universe
200M Protein Structures: DeepMind's 2025 breakthrough predicts 98% accuracy across 800M complexes, tripling viable targets from 10K to 30K druggable proteins.Pharma Adoption Surge: 75% top-20 pharma license AlphaFold3, accelerating antibody design 40% faster with 85% binding prediction success.
​
▪ Generative AI Designs Novel Molecules
De Novo Drug Creation: Exscientia's AI generates clinical-ready molecules in 8 months vs 4 years, with 70% improved binding affinity over HTS libraries.
​125M Compound Expansion: Atomwise AtomNet explores 3 trillion virtual compounds, identifying 5x more hits than physical screening at 90% accuracy.

▪ Clinical Trial Success Rates Double
Patient Matching Precision: ML models boost Phase II-III success from 30% to 58% by predicting responders with 92% accuracy using multi-omics data.
​$1.2B Synthetic Control Arms: FDA accepts AI-generated controls replacing 40% traditional patients, cutting trial costs 35% and timelines 6 months.

Ai in drug discovery and development Market Regional Insights:-

North America: 67.2% Global Share
North America dominates with 67.2% market share in 2025, fueled by $60B+ VC investments and 75% Big Pharma AI adoption led by U.S. biotech hubs.U.S. holds 56.18% regional dominance as FDA fast-tracks 15 AI-designed candidates, compressing discovery timelines 40% via DeepMind collaborations.

Asia Pacific: 21% Share, 29.8% CAGR
APAC grows fastest at 29.8% CAGR through 2034, driven by China's $10B AI pharma fund and India's 1M+ AI researchers powering virtual screening.Japan/South Korea deploy 5G-enabled data lakes, supporting WuXi AppTec's 100+ monthly AI campaigns across regional partnerships.
​
Europe: 17.2% Share
Europe captures 17.2% led by UK Exscientia's first AI drug in Phase II and BenevolentAI's COVID repurposing success story.
​Germany/France invest €2B in AI consortia, generating 50+ novel targets annually through knowledge graph technologies.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/ai-in-drug-discovery-and-development-market?prtk

Ai in drug discovery and development Market Market Segmentation

Technology Segmentation
Machine Learning (45% share): Predictive models screen 10B compounds/second, cutting discovery costs 60% from $2.6B average.
Deep Learning (28% share): Neural networks predict protein-ligand binding with 90% accuracy vs 65% traditional docking.
Generative AI (18% share): Designs novel molecules in 8 months vs 4 years, powering Exscientia's Phase II candidates.
Natural Language Processing (9% share): Analyzes 100TB biomedical literature daily for target identification.

Application Segmentation
Target Identification (32% share): AlphaFold3 unlocks 30K druggable proteins, tripling viable targets from 10K.
Lead Optimization (25% share): Atomwise improves binding affinity 70% faster than HTS libraries.
De Novo Drug Design (22% share): AI generates clinical-ready molecules, compressing FIH timelines to 18 months.
Clinical Trial Optimization (21% share): Synthetic controls cut costs 35%, boosting Phase II success from 30% to 58%.

This research report delivers actionable insights, data-driven analysis, and future-ready perspectives that enable informed decision-making, reduce market risks, and uncover growth opportunities across the industry

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.